Cardiovascular Diseases in Psoriasis and Psoriatic Arthritis

Lihi Eder, Amit Dey, Aditya A. Joshi, Wolf-Henning Boehncke, Nehal N. Mehta, and Agnes Szentpetery

ABSTRACT. Patients with psoriatic disease have an increased risk of developing cardiovascular (CV) events. Recent advances in imaging and biomarker research provide insights into the underlying mechanisms that link these conditions. Here, we summarize recent work in this field that was presented at the July 2018 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting in Toronto, Ontario, Canada. The presentations highlighted recent data about the association between psoriasis and vascular inflammation, the use of coronary angiogram to investigate CV outcomes, new approaches for CV risk stratification, and the shared pathomechanisms of psoriasis and atherosclerosis. (J Rheumatol Suppl. 2019 June;95:20–7; doi:10.3899/jrheum.190114)

Key Indexing Terms:

PSORIASIS

PSORIATIC ARTHRITIS

GRAPPA

CARDIOVASCULAR DISEASE

MYOCARDIAL INFARCTION

Patients with psoriasis and psoriatic arthritis (PsA) have an increased risk of developing cardiovascular diseases (CVD). Recent advances in imaging and biomarker research have provided insight into some of the underlying mechanisms that link these conditions. Here, we summarize recent work in this field that was presented at the July 2018 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting in Toronto, Ontario, Canada.

Vascular Inflammation and Psoriasis

Dr. Nehal Mehta (Bethesda, Maryland, USA) discussed the relationship between systemic inflammation and CVD in psoriasis. His presentation focused on the pivotal role of

inflammation in the development of atherosclerosis and how it accounts for about 20–30% of residual risk for incident acute myocardial infarction (MI)¹.

Recently, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study trial demonstrated that mitigation of residual inflammation with antiinflammatory therapy — an interleukin (IL)-1 β inhibitor — contributed to a reduction in CV risk that was independent of lipid-level lowering, thus cementing the role of inflammation in CVD². Considering the inflammatory mechanisms that are inherent to both the skin and coronary artery disease (CAD), psoriasis can be used as a human model to understand the effect of chronic inflammation on CVD. Moreover, a National Institutes of Health (NIH)-funded cohort study is examining the link between psoriasis and early atherosclerosis in detecting early vascular diseases through the use of advanced imaging techniques, including fluorodeoxyglucose (FDG) imaging in positron emission tomography (PET).

Aortic vascular inflammation (VI) by FDG-PET/computed tomography (CT) has emerged as an important biomarker of CV risk. Studies in the past have shown that FDG in the vessel walls is taken up by macrophages, which are CD68+ cells relevant to the process of atherogenesis. Moreover, aortic VI is associated with inflammatory biomarkers, marks the distribution of atherosclerotic plaques with high-risk morphological features in the coronary arteries, and is strongly predictive of future CV events (CVE)³. Additionally, VI is highly sensitive to modulation in risk factors with preventive strategies such as statin therapy⁴ as well as to therapeutic lifestyle changes⁵ that are known to mitigate CV risk. Therefore, VI by FDG-PET/CT provides a reliable surrogate to study factors that have an effect on CV risk. FDG-PET/CT VI was shown to be a reliable surrogate

From the Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada; Laboratory of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, Maryland, USA; Division of Dermatology and Venereology, Geneva University Hospitals, and Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; Department of Rheumatology, Uppsala University Hospital, Uppsala, Sweden.

As part of the supplement series GRAPPA 2018, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards.

L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; A. Dey, MD, Laboratory of Inflammation and Cardiometabolic Diseases, NHLBI, NIH; A.A. Joshi, MD, Laboratory of Inflammation and Cardiometabolic Diseases, NHLBI, NIH; W.H. Boehncke, MD, Professor and Chair, Division of Dermatology and Venereology, Geneva University Hospitals, and Department of Pathology and Immunology, University of Geneva; N.N. Mehta, MD, MSCE, Laboratory of Inflammation and Cardiometabolic Diseases, NHLBI, NIH; A. Szentpetery, MD, PhD, Department of Rheumatology, Uppsala University Hospital.

*Address correspondence to Dr. L. Eder, Women's College Hospital, 76 Grenville St., Toronto, Ontario M5S 1B2, Canada.
E-mail: Lihi.EDER@wchospital.ca*

marker in demonstrating that psoriasis is associated with subclinical atherosclerosis⁶. Naik, *et al* further showed that VI by FDG-PET/CT is associated with psoriasis severity, which suggests there are shared mechanisms between remote inflammation in the skin and the presence of vascular disease⁶. Finally, in an observational study design, the increase in aortic VI was shown to be attenuated following biologic psoriasis therapy concurrent with improved psoriasis severity, which suggests that quelling inflammation has a beneficial effect on aortic VI over time⁷. Although highly informative, a considerable limitation of these studies is that they did not characterize the CAD.

In parallel, our group used coronary computed tomography angiography (CCTA) to obtain a reliable noninvasive assessment of coronary plaque composition as well as a volumetric quantification of CAD⁸. Studies have shown that lipid-rich noncalcified plaque volumes and high-risk plaque features by CCTA are elevated in MI, and that they undergo reduction after intensive statin treatment⁹ and other CV risk-mitigating therapies¹⁰. Using this concept, our group subsequently showed by CCTA that psoriasis was also associated with increased lipid-rich noncalcified plaque and high-risk coronary plaque¹¹, which are both reliable surrogate markers for prospective CVD⁸. Further, in a subset of the first consecutive 50 patients, our group showed that the reduction in psoriasis severity was associated with the reduction in lipid-rich plaque at 1 year following treatment of psoriasis with biologic agents. Taking this concept even further, the laboratory's current efforts are focused on the effect of biological therapy on lipid-rich noncalcified as well as high-risk coronary plaque burden by CCTA over time in psoriasis. These findings show that biologic therapy for psoriasis reduced coronary plaque over 1 year compared to nonbiologic therapy¹². Around this time, the National Heart, Lung, and Blood Institute (NHLBI) and the University of Pennsylvania carried out a phase III, double-blind, randomized controlled clinical trial to assess the effect of tumor necrosis inhibitor (TNFi) therapy on aortic VI¹³. Aortic VI was measured from FDG-PET/CT scans at baseline visit and at 12-week and 1-year timepoints using previously published and validated methods⁶. The trial results demonstrated that treatment of psoriasis with the TNFi agent adalimumab reduced key markers of inflammation at both 12-week and 1-year followup, including GlycA, a novel nuclear magnetic resonance spectroscopy-derived composite biomarker of inflammation, compared to phototherapy. There was no effect, however, on the treatment of aortic VI, with warnings of worsening lipid variables that included a reduction in high-density lipoprotein function and an increase in low-density lipoprotein. These data provide potential context to the benefit of antiinflammatory therapy that has been seen in observational studies¹⁴, which may partially have been explained by the beneficial effects on GlycA.

Next, the NHLBI team was interested in understanding

how aortic VI might relate to coronary plaque in psoriasis. In 215 consecutive psoriasis patients who underwent concurrent FDG-PET/CT imaging and CCTA, the team characterized CAD using 3 measures: quantitative total and noncalcified coronary plaque burden, luminal stenosis, and high-risk plaque characterization. While aortic VI assesses the uptake of FDG in inflamed regions of aortic wall, CCTA provides a direct visualization of coronary anatomy and characterizes atherosclerotic plaque burden within the coronary arteries. The study demonstrated the severity and extent of VI in the aortic wall of patients with psoriasis. It also established a direct association between the aortic VI and broad measures of CAD, including total and noncalcified quantitative coronary plaque burden, luminal stenosis, stenosis severity within the major epicardial coronary arteries, and the prevalence of high-risk plaque¹⁵. These results demonstrate the promise of aortic VI in capturing early high-risk CAD.

Collectively, since the first FDG-PET/CT image in psoriasis was taken in 2012, much has occurred to define psoriasis as a whole-body disease that increases the risk of atherosclerosis. The link between inflammation and CVD using psoriasis as a human disease model has shifted the paradigm of care to focus on treating psoriasis, while also improving the risk stratification and risk prediction of CVD. Imaging vascular diseases with FDG-PET/CT or CCTA has its limitations, including that it is a surrogate marker and that it lacks spatial resolution beyond 2 mm. However, as studies continue to apply a diverse set of scientific approaches to move discoveries from bench to bedside, our understanding of the drivers of these high-risk atherosclerotic features will continue to improve.

New Insights in CVD in Psoriatic Disease

Dr. Lihi Eder (Toronto, Ontario, Canada) presented her team's research about CVD in patients with psoriasis and PsA, novel approaches to CV risk stratification through the use of laboratory biomarkers and imaging, and the effect of TNFi on CV outcomes.

CV risk stratification and the management of CV risk factors in psoriatic patients are integral parts of patient care. Current treatment guidelines recognize the need to identify patients who are at high CV risk based on accepted clinical risk scores¹⁶. But traditional CV risk scores underestimate CV risk in psoriatic patients¹⁷, most likely because these risk scores do not account for the effect of systemic inflammation. Because of this, these patients are often underdiagnosed and undertreated for CV risk factors¹⁸. This has a potential adverse effect on clinical CV outcomes and warrants optimization of CV risk stratification tools that are designed for use in this population.

Eder, *et al* evaluated the role of vascular imaging as a tool to improve CV risk stratification. The group hypothesized that the quantification of atherosclerotic plaque burden through the use of carotid ultrasound (US) could potentially

provide a more accurate evaluation of the effect of traditional and nontraditional risk factors on CV risk and may also improve the precision of CV risk stratification tools for use in psoriatic patients. The group performed a cohort analysis of 607 patients from the University of Toronto Psoriasis and PsA Cohort that were followed at 6- to 12-month intervals from 2010 to 2017 using standard protocols. Patients underwent US assessment of the carotid arteries at baseline¹⁹. The extent of atherosclerosis was assessed using carotid intima-media thickness (cIMT) and total plaque area (TPA). Incident CVE that occurred following US assessment were recorded. The group found that 37 patients developed incident CVE, which resulted in a calculated rate of 1.67 events per 100 patient-years. A higher burden of atherosclerotic plaques in the carotid arteries, as measured by TPA and cIMT, was associated with an increased risk of developing CVE. This association remained statistically significant after adjusting for traditional CV risk factors. In multivariable regression models, TPA (HR 2.20; $p < 0.001$), mean cIMT (HR 1.21; $p < 0.001$), bilateral plaques versus no plaques (HR 2.89; $p = 0.03$), and high TPA category (HR 2.77; $p = 0.009$) predicted incident CVE after controlling for the Framingham Risk Score. The results were similar after restricting the analysis to patients with no prior history of CVD at baseline. These results suggest that combining vascular imaging data with information on traditional CV risk factors could improve the accuracy of CV risk stratification in psoriatic patients.

Eder, *et al* also investigated the role of metabolic biomarkers in atherosclerosis in psoriatic disease. Metabolomic profiling offers an unparalleled opportunity to unravel the molecular and clinical interactions that link psoriatic disease with CV risk. The group used high-throughput serum nuclear magnetic resonance metabolomics to quantify the levels of 58 serum metabolites including lipoprotein subclasses, fatty acid composition, amino acids glycolysis precursors, and ketone bodies among patients with psoriasis, PsA, and controls²⁰. The group found differences in the levels of 19 metabolites between psoriatic patients and controls, including abnormal levels of lipoprotein subclasses, fatty acids, amino acids, and intermediates of glycolysis. It then evaluated the incremental value of adding circulating metabolites to established CV risk factors to predict atherosclerosis progression through regression analysis. They found that 13 metabolites, primarily atherogenic lipid particles, predicted atherosclerosis progression after adjusting for CV risk factors. This study highlights the association between an abnormal metabolomic profile and psoriatic disease. Atherogenic lipoprotein particles across the non-high-density lipoprotein cholesterol spectrum predicted atherosclerosis progression in psoriatic patients independent of conventional CV risk factors. The group plans to further investigate the role of these biomarkers in the prediction of CVE in psoriatic patients, which can be used to improve CV risk stratification.

Last, Dr. Eder presented a study that evaluated the effect

of TNFi on subclinical CVD in psoriatic patients. The suppression of inflammation using immunomodulating agents may represent a promising new target for the management of CVD in patients with chronic inflammatory conditions, because the ensuing benefits may apply beyond the skin and joint disease²¹. There is limited and conflicting data regarding the effect of TNFi on CVE in psoriatic disease²². In collaboration with a team from the NIH led by Dr. Mehta, the group performed a 2-stage prospective cohort study to assess the effect of TNFi on subclinical CVD in patients with psoriasis and PsA. Carotid atherosclerosis progression and aortic VI, as measured by FDG-PET/CT, were considered as a surrogate measure of CV risk. The use of TNFi was associated with a lower rate of progression of atherosclerotic plaques (among men) and reduced VI during the followup period independent of traditional CV risk factors. These results highlight the potential cardio-protective effect of TNFi among psoriatic patients. However, more research is needed to confirm these results and to understand the underlying mechanisms that are driving atherogenesis in psoriasis and PsA.

Cardiovascular Outcomes in Psoriatic Disease and Use of CCTA

Dr. Agnes Szentpetery (Uppsala, Sweden) discussed the role of CCTA in the detection of coronary plaques and its implications in psoriasis and PsA.

In a population-based longitudinal study, patients with PsA displayed a higher risk of MI compared to controls, similar to those with severe psoriasis and rheumatoid arthritis patients who are not prescribed disease-modifying anti-rheumatic drugs²³. This accelerated CV risk is not accurately recorded through traditional risk assessment²⁴, and there remains an unmet need for identifying and addressing CV risk in psoriatic disease. It has been widely accepted that the presence of carotid plaques increases the risk of CVE. US studies have shown a higher prevalence of carotid artery plaques in patients with psoriasis and PsA²⁵ compared with healthy controls. PsA patients have more severe subclinical atherosclerosis compared with those with psoriasis alone, independent of traditional CV risk factors²⁵.

It has been suggested that PsA patients with carotid plaque should be considered to have a very high CV risk²⁶; however, the presence of carotid artery plaque alone is not sufficient to identify patients at risk for CAD²⁷. The standardized prevalence ratio for CAD in patients with PsA ranges from 1.3 to 2.57²⁸. Even though high CV risk is likely attributed to an increased burden of subclinical CAD in patients with psoriatic disease, to date, inadequate efforts have been made to directly measure CAD in this vulnerable population¹¹.

CCTA is an established noninvasive, highly accurate, and reproducible CV imaging technique that gives direct anatomic visualization of the coronary artery wall and provides information on plaque localization, size, and

severity of luminal restriction. A major advantage over invasive angiography is CCTA's ability to assess the nonstenosing atherosclerosis burden within the vessel wall, which is underestimated by invasive coronary angiography²⁹. CCTA reliably measures the overall plaque burden, differentiates between plaque subtypes, and identifies vulnerable, high-risk coronary atherosclerotic plaques³⁰. Coronary lesions prone to rupture are frequently referred to as having a thin-cap fibroatheroma with a large necrotic core and a thin fibrous cap that is infiltrated by macrophages and T lymphocytes. These lipid-rich plaques have a high likelihood of rupture and are therefore likely to precipitate thrombosis. This can lead to an acute coronary syndrome. The presence of vulnerable plaques on CCTA is strongly associated with an increased risk of future major adverse cardiac events³¹.

Studies assessing coronary plaque burden with CCTA in psoriasis and PsA are scarce. An increased prevalence and severity of coronary artery calcification has been found in patients with psoriasis compared to controls matched for age, sex, and CV risk factors; however, these studies did not thoroughly evaluate individual coronary arteries for the severity of CAD³². Hjuler, *et al* compared the prevalence, severity, and subtypes of coronary plaques between patients with severe psoriasis [Psoriasis Area and Severity Index (PASI) > 10], atopic dermatitis (AD), and asymptomatic controls without known CVD. They found that both psoriasis and AD were associated with an increased prevalence of coronary plaques, but psoriasis patients had more proximal lesions, as well as a higher prevalence of significant stenosis and 3-vessel disease than patients with AD. Plaque burden was correlated with age, hyperlipidemia, and diabetes but not with disease duration³³.

The same group investigated the progression of CAD in patients with severe psoriasis who did not have symptomatic CAD, using CCTA after initiating a biological treatment. While coronary atherosclerosis remained stable in patients receiving biological therapy at 13 months, coronary artery calcium scores, severity of luminal narrowing, and vessel wall volume showed a significant progression in controls who were not treated with a systemic therapy³⁴. This suggests that the improvement in skin inflammation may be associated with a reduction in CV risk in patients with psoriasis.

Lerman, *et al* compared total and noncalcified coronary plaque burden and high-risk plaque prevalence as measured by CCTA between psoriasis patients, hyperlipidemic patients who were 10 years older (and eligible for statin therapy by National Cholesterol Education Program Adult Treatment Panel III guidelines), and healthy volunteers without psoriasis¹¹. A consecutive sample of the first 50 psoriasis patients was scanned again following 1 year of systemic biologic treatment. Patients with psoriasis had an increased noncalcified plaque burden and an equivalent prevalence of high-risk plaque compared to older patients with hyperlipi-

demia who had a higher CV risk by traditional risk scores. Improvement in the PASI score was associated with an improvement in noncalcified coronary plaque burden over 1 year, which suggests that the control of skin inflammation may translate into a reduced risk of CAD in psoriasis¹¹.

To date, there are limited data available on CAD as assessed by CCTA in PsA. Shen, *et al* reported an increased prevalence, burden, and severity of calcified, mixed, and noncalcified coronary plaque in patients with PsA who did not have a prior CAD diagnosis, compared to healthy controls³⁵. This study, however, provided only a qualitative description of coronary plaques. After adjusting for traditional CV risk factors, PsA remained an independent factor for all types of coronary plaques. Age, male sex, and disease duration were associated with the presence of vulnerable plaques.

Dr. Szentpetery presented findings from her group's study from St. Vincent's University Hospital, Ireland, that analyzed coronary plaque burden and plaque composition. The study provided detailed plaque volume measurements using a 64-slice CCTA in 50 PsA patients without symptoms or diagnosis of CAD (25 with metabolic syndrome and 25 without metabolic syndrome) compared to 50 age- and sex-matched controls³⁶. Patients with well-established PsA had a higher presence and extent of coronary plaques, particularly of vulnerable mixed plaque type, compared to controls. More PsA patients had plaques with higher plaque volume in the proximal left anterior descending coronary segments, which are known to be associated with a poorer prognosis of CAD. Age, maximum C-reactive protein (CRP) during the disease course, maximum number of swollen joints, disease duration, and plasma glucose were independent predictors of a higher plaque burden in PsA. Total plaque volume in the coronary arteries was associated with a diagnosis of PsA but not with metabolic syndrome. The results suggest that the accelerated formation of coronary plaques in PsA may be associated with underlying disease activity and severity, but this is independent of features of metabolic syndrome³⁶.

Dr. Szentpetery highlighted that translating the identification of elevated coronary plaque burden in PsA patients into preventative interventions to reduce future CV events remains challenging. First, studies on the effect of disease activity on CAD are scarce in psoriatic disease. Second, there is a lack of evidence about a protective effect of more aggressive treatment for reducing the risk of adverse CV outcomes. Third, studies that demonstrate associations between carotid and coronary plaque burden are limited in PsA. Because of this, larger studies are needed to evaluate the clinical values of CCTA in the prediction of future coronary artery events in PsA, particularly in patients with active and more severe forms of the disease.

Psoriasis and Atherosclerosis—Shared Pathomechanisms

Dr. Wolf-Henning Boehncke (Geneva, Switzerland) from the Geneva University Hospitals discussed shared pathomech-

anisms of psoriasis and atherosclerosis.

One of the first systematic analyses on disease concomitance identified an association of psoriasis with CVD, as well as other diseases that represent risk factors for atherosclerosis, such as diabetes mellitus or obesity. The authors concluded that a distinct pattern of associated diseases exists in patients with psoriasis, suggesting a genetically determined selection. Since then, multiple epidemiologic studies have addressed the issue of CV comorbidity in patients with psoriasis. While some groups concluded that such a link does not exist, many others were able to reproduce this association, which was recently summarized elsewhere³⁷. Based on the currently available evidence, most experts agree that the association of psoriasis with CV comorbidity is real.

The question arises regarding why CVD are associated with psoriasis. A strong argument in favor of an indirect link comes from the observation that psoriasis is associated with numerous conditions that represent major CV risk factors on their own, as discussed above. Evidence in favor of psoriasis as an independent CV risk factor comes from studies showing a “dose effect” of psoriasis on patients’ CV risk. A landmark study conducted by Gelfand, *et al* used data from the General Practice Research Database from 1987 to 2002, comprising prospective data collected from general practitioners in Britain³⁸. After adjusting for major CV risk factors, such as hypertension, diabetes mellitus, and hyperlipidemia, the group found a slightly elevated adjusted relative risk for MI among patients with mild psoriasis and a substantially elevated adjusted relative risk among patients with severe psoriasis³⁸. The clinical relevance of psoriasis as an independent CV risk factor was quantified by Mehta, *et al* in a cohort study of severe psoriasis patients³⁹. In this study, the attributable risk of severe psoriasis on major CVE (i.e., MI and stroke) over a 10-year period was found to be around 6%³⁹. Taken together, despite a few studies that did not show statistically significant associations between psoriasis and major CVE, a majority of studies that used different methodical approaches not only suggests an association between psoriasis and CVD, but also provides evidence that psoriasis is an independent CV risk factor.

One possible explanation of the association of psoriasis with its comorbid conditions in general and CVD in particular is that these entities share common genetics. Indeed, Cheng, *et al*, observed a possible genetic link between psoriasis and CV comorbidity. They interpreted a missense mutation in the insulin-responsive leucyl and cystinyl aminopeptidase as a potential link among psoriasis, hypertension, and diabetes mellitus⁴⁰. Conversely, a comprehensive assessment of the catalogue of genome-wide association studies by Gupta, *et al* showed that the genetic control of psoriasis is almost completely independent from both the metabolic syndrome and coronary heart disease⁴¹. To prove the reliability of this approach, the authors were able to identify 10 common loci for metabolic syndrome and

coronary heart disease using exactly the same dataset. Taken together, the observed association of psoriasis with CV comorbidity cannot satisfyingly be explained by shared genetics.

To this end, epidemiological evidence has been summarized in favor of the association of psoriasis and CV comorbidity. The former potentially functions as an independent CV risk factor. Because genetic overlap cannot satisfyingly explain the excessive CV risk of patients with severe psoriasis, mechanistic studies are needed to further clarify the link. The cardiologist Späth was among the first to discuss a potentially common inflammatory pathway and the idea of an integrated treatment approach⁴². He stressed altered endothelial function, the subsequent recruitment of leukocytes and primarily T lymphocytes, and the development of lesions as shared early steps in the process of plaque formation in atherosclerosis and psoriasis. Meanwhile, many more shared mechanisms of atherosclerosis and psoriasis have been studied in detail⁴³.

Thus, over the last decade, multiple shared pathogenetic mechanisms have been identified in psoriatic and atherosclerotic plaque formation. These similarities do not, however, explain why psoriasis might actually represent an independent CV risk factor, as suggested by the majority of epidemiologic studies. Of considerable importance in this regard is the notion that psoriasis cannot be regarded as isolated cutaneous inflammation but instead represents a chronic systemic inflammatory disease. To this end, several groups have identified biomarkers of inflammation in the blood of psoriasis patients that correlate with psoriasis severity, such as CRP, erythrocyte sedimentation rate⁴⁴, and the platelet activation marker P-selectin⁴⁵.

The concept of the “psoriatic march” provides a framework to explain how psoriatic inflammation drives CV comorbidity by atherosclerosis independent from the presence of additional CV risk factors⁴⁶. According to this concept, psoriasis is a chronic systemic inflammatory disorder, as evidenced by elevated biomarkers of systemic inflammation. It is noteworthy that, in addition to the elevation of classical markers for systemic inflammation, resistin and leptin are also elevated⁴⁷. These belong to a family of mediators secreted by adipocytes called adipokines. Resistin and leptin are insulin-antagonizing adipokines. Collectively, the adipokine milieu in the blood of patients with psoriasis is strikingly similar to that of prediabetic individuals, and warns of a state of insulin resistance. At the level of endothelial cells, insulin resistance is thought to induce endothelial dysfunction and vascular stiffness at the functional level. Indeed, several groups found evidence for endothelial dysfunction. In particular, flow-mediated vascular dilation was impaired⁴⁸. This cascade drives atherosclerosis, which ultimately causes CVD such as MI and stroke.

As a footnote, inflammation-induced insulin resistance may help to explain the altered homeostasis that is observed

in the epidermis of psoriatic plaques, a phenomenon that might have implications beyond psoriasis⁴⁹.

The state of chronic systemic inflammation in psoriasis may at least contribute to atherosclerosis through insulin resistance and endothelial dysfunction and therefore may be partially responsible for the increased CV risk of patients with severe psoriasis. This raises the question whether continuous systemic antiinflammatory treatments may help to reduce this excessive risk. An early hint that continuous systemic anti-inflammatory treatment might reduce the CV risk of psoriasis came from a retrospective study by Prodanovich, *et al*, who analyzed the files of more than 7000 American veterans who had been treated over extended periods with methotrexate (MTX) for their psoriasis⁵⁰. The researchers found a significantly reduced incidence of CVD in these patients. Since then, several observational studies analyzing the effects of MTX or TNF- α inhibitors came to similar conclusions⁵¹, while others failed to document such protective effects⁵². Complementary to these studies, small controlled trials were performed that evaluated changes of biomarkers for CV risk under systemic antipsoriatic treatment. Indeed, several groups reported amelioration of such markers under successful therapy. These include cytokines, adipokines, endothelial dysfunction, and cIMT^{53,54}.

Based on some of these observations, more ambitious projects were launched that were sponsored by pharmaceutical companies. A pilot study on 30 patients with psoriasis looked at VI in the ascending aorta and carotid arteries by means of PET/CT. In that study, decreases in VI were observed in patients treated with adalimumab (ADA) compared with placebo when data for the ascending aorta and carotid arteries were analyzed separately at 15 weeks⁵⁵. A larger study that included 107 patients showed no difference over 16 weeks in the adalimumab-treated group compared to placebo and a modest increase in VI in the carotid arteries after 52 weeks of treatment with adalimumab⁵⁶. A commentary on that publication suggested that the study might have been too small or of insufficient duration to show an effect, and that it was the carotid arteries and ascending aorta that were studied, not the coronary arteries, which might explain the negative result⁵⁷. Another study (as yet unpublished) using the IL-17A blocking antibody secukinumab was performed in a multicenter setting in Germany. An abstract presented at the congress of the European Academy for Dermatology and Venereology in Geneva in 2017 documented a trend toward improvement in vascular elasticity, but no data from that trial have so far been published in a peer-reviewed manner.

There is some evidence in support of reducing the excess CV risk of patients with psoriasis through systemic anti-inflammatory therapy. Although this approach remains intellectually appealing, it may be more effective and efficient in a real-world scenario to address other major CV risk factors that are associated with psoriasis to reduce excessive CV risk.

Examples are appropriate treatment of the metabolic syndrome or components thereof, or lifestyle interventions such as smoking cessation.

REFERENCES

- Harrington RA. Targeting inflammation in coronary artery disease. *N Engl J Med* 2017;377:1197-8.
- Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017;377:1119-31.
- Joshi AA, Lerman JB, Abera TM, Afshar M, Teague HL, Rodante JA, et al. GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis. *Circ Res* 2016;119:1242-53.
- Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: Results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. *J Am Coll Cardiol* 2013;62:909-17.
- Lee SJ, On YK, Lee EJ, Choi JY, Kim BT, Lee KH. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. *J Nucl Med* 2008;49:1277-82.
- Naik HB, Natarajan B, Stansky E, Ahlman MA, Teague H, Salahuddin T, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. *Arterioscler Thromb Vasc Biol* 2015;35:2667-76.
- Dey AK, Joshi AA, Chaturvedi A, Lerman JB, Abera TM, Rodante JA, et al. Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography/computed tomography. *JAMA Cardiol* 2017;2:1013-8.
- Motoyama S, Ito H, Sarai M, Kondo T, Kawai H, Nagahara Y, et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. *J Am Coll Cardiol* 2015;66:337-46.
- Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet HIV* 2015;2:e52-63.
- Vaidya K, Arnott C, Martinez GJ, Ng B, McCormack S, Sullivan DR, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT coronary angiography study. *JACC Cardiovasc Imaging* 2018;11:305-16.
- Lerman JB, Joshi AA, Chaturvedi A, Abera TM, Dey AK, Rodante JA, et al. Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study. *Circulation* 2017;136:263-76.
- Elnabawi YA, Varghese NJ, Sanda GE, Dey AK, Groenendyk JW, Genovese LD, et al. Abstract 12596: immunomodulatory therapy favorably modifies coronary plaque morphology in psoriasis [abstract]. *Circulation* 2018;138:A12596.
- Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial. *Circ Cardiovasc Imaging* 2018;11:e007394.
- Wu JJ, Poon KY, Bebachuk JD. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. *J Drugs Dermatol* 2013;12:899-903.
- Joshi AA, Lerman JB, Dey AK, Sajja AP, Belur AD, Elnabawi YA,

- et al. Association between aortic vascular inflammation and coronary artery plaque characteristics in psoriasis. *JAMA Cardiol* 2018;3:949-56.
16. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Ann Rheum Dis* 2017;76:17-28.
 17. Eder L, Chandran V, Gladman DD. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. *Ann Rheum Dis* 2014;73:1990-6.
 18. Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, et al. Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: an international multicenter study. *J Rheumatol* 2018;45:378-84.
 19. Sobchak C, Akhtari S, Harvey P, Gladman D, Cook R, Eder L. The value of carotid ultrasound in cardiovascular risk stratification in patients with psoriatic disease [abstract]. *Arthritis Rheumatol* 2017;69 Suppl 10:1608.
 20. Eder L, Harvey P, Welsh P, Chandran V, McInnes I, Cook R, et al. Metabolomics profile predicts carotid atherosclerosis progression in psoriatic disease [abstract]. *Arthritis Rheumatol* 2018;70 Suppl 10:1590.
 21. Ridker PM. Moving beyond JUPITER: Will inhibiting inflammation reduce vascular event rates? *Curr Atheroscler Rep* 2013;15:295.
 22. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. *Ann Rheum Dis* 2015;74:480-9.
 23. Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. *Ann Rheum Dis* 2015;74:326-32.
 24. Haroon M, Szentpetery A, Dodd JD, Fitzgerald O. Modifications of cardiovascular risk scores, but not standard risk scores, improve identification of asymptomatic coronary artery disease in psoriatic arthritis. *J Rheumatol* 2018;45:1329-30.
 25. Eder L, Jayakar J, Shanmugarajah S, Thavaneswaran A, Pereira D, Chandran V, et al. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. *Ann Rheum Dis* 2013;72:715-20.
 26. Lucke M, Messner W, Kim ES, Husni ME. The impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis. *Arthritis Res Ther* 2016;18:178.
 27. Svanteson M, Rollefstad S, Klow NE, Hisdal J, Ikdahl E, Semb AG, et al. Associations between coronary and carotid artery atherosclerosis in patients with inflammatory joint diseases. *RMD Open* 2017;3:e000544.
 28. Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. *Ann Rheum Dis* 2015;74:1830-5.
 29. Eckert J, Schmidt M, Magedanz A, Voigtlander T, Schmermund A. Coronary CT angiography in managing atherosclerosis. *Int J Mol Sci* 2015;16:3740-56.
 30. Carita P, Guaricci AI, Muscogiuri G, Carrabba N, Pontone G. Prognostic value and therapeutic perspectives of coronary CT angiography: a literature review. *Biomed Res Int* 2018;2018:6528238.
 31. Bom MJ, van der Heijden DJ, Kedhi E, van der Heyden J, Meuwissen M, Knaapen P, et al. Early detection and treatment of the vulnerable coronary plaque: Can we prevent acute coronary syndromes? *Circ Cardiovasc Imaging* 2017;10: e005973.
 32. Yiu KH, Yeung CK, Zhao CT, Chan JC, Siu CW, Tam S, et al. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. *J Intern Med* 2013;273:273-82.
 33. Hjuler KF, Bottcher M, Vestergaard C, Deleuran M, Raaby L, Botker HE, et al. Increased prevalence of coronary artery disease in severe psoriasis and severe atopic dermatitis. *Am J Med* 2015;128:1325-34.
 34. Hjuler KF, Bottcher M, Vestergaard C, Botker HE, Iversen L, Kragballe K. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. *JAMA Dermatol* 2016;152:1114-21.
 35. Shen J, Wong KT, Cheng IT, Shang Q, Li EK, Wong P, et al. Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. *Ann Rheum Dis* 2017;76:1237-44.
 36. Szentpetery A, Healy GM, Brady D, Haroon M, Gallagher P, Redmond CE, et al. Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. *Arthritis Rheumatol* 2018;70:396-407.
 37. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. *J Am Acad Dermatol* 2017;76:377-90.
 38. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA* 2006;296:1735-41.
 39. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. *Am J Med* 2011;124:775.
 40. Cheng H, Li Y, Zuo XB, Tang HY, Tang XF, Gao JP, et al. Identification of a missense variant in LNPEP that confers psoriasis risk. *J Invest Dermatol* 2014;134:359-65.
 41. Gupta Y, Moller S, Zillikens D, Boehncke WH, Ibrahim SM, Ludwig RJ. Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease. *Exp Dermatol* 2013;22:552-3.
 42. Späth F. Inflammation in atherosclerosis and psoriasis: Common pathogenic mechanisms and the potential for an integrated treatment approach. *Br J Dermatol* 2008;159 Suppl 2:10-7.
 43. Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. *Front Immunol* 2018;9:579.
 44. Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, et al. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. *Clin Exp Dermatol* 2011;36:845-50.
 45. Garbaraviciene J, Diehl S, Varwig D, Bylaite M, Ackermann H, Ludwig RJ, et al. Platelet P-selectin reflects a state of cutaneous inflammation: Possible application to monitor treatment efficacy in psoriasis. *Exp Dermatol* 2010;19:736-41.
 46. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. *Exp Dermatol* 2011;20:303-7.
 47. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, et al. Psoriasis patients show signs of insulin resistance. *Br J Dermatol* 2007;157:1249-51.
 48. Gisondi P, Fantin F, Del Giglio M, Valbusa F, Marino F, Zamboni M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. *Dermatology* 2009;218:110-3.
 49. Malisiewicz B, Boehncke S, Lang V, Boehncke WH, Buerger C. Epidermal insulin resistance as a therapeutic target in acanthosis nigricans? *Acta Derm Venereol* 2014;94:607-8.
 50. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. *J Am Acad Dermatol* 2005;52:262-7.
 51. Wu JJ, Poon KY, Channal JC, Shen AY. Association between tumor

- necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. *Arch Dermatol* 2012;148:1244-50.
52. Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. *Br J Dermatol* 2011;165:1066-73.
 53. Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Hardt K, Diehl S, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. *J Eur Acad Dermatol Venereol* 2011; 25:1187-93.
 54. Boehncke S, Fichtlscherer S, Salgo R, Garbaraviciene J, Beschmann H, Diehl S, et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. *Arch Dermatol Res* 2011;303:381-8.
 55. Bissonnette R, Tardif JC, Harel F, Pressacco J, Bolduc C, Guertin MC. Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. *Circ Cardiovasc Imaging* 2013;6:83-90.
 56. Bissonnette R, Harel F, Krueger JG, Guertin MC, Chabot-Blanchet M, Gonzalez J, et al. TNF- α antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study. *J Invest Dermatol* 2017;137:1638-45.
 57. Lebwohl M. Does treatment of psoriasis reduce cardiovascular comorbidities? *J Invest Dermatol* 2017;137:1612-3.